IGFBPL1 Antibodies

Santa Cruz Biotechnology features a diverse variety of IGFBPL1 monoclonal antibodies for investigating Insulin-like Growth Factor Binding Protein Like 1 (IGFBPL1). IGFBPL1 monoclonal antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). IGFBPL1 plays a critical role in modulating the actions of insulin-like growth factors (IGFs), which are essential for cell growth, development, and metabolism. By binding to IGFs, IGFBPL1 influences their availability and activity, impacting cellular signaling pathways and physiological processes. Research has shown that IGFBPL1 expression patterns vary across different tissue types and developmental stages. Understanding IGFBPL1 function and regulation provides valuable insights into its role in various diseases, including cancer and metabolic disorders. Ongoing studies continue to reveal new aspects of IGFBPL1 biology and its significance in cellular processes. Current research focuses on exploring IGFBPL1's potential as a therapeutic target. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance scientific understanding of IGFBPL1 and its impact on human health.